20213078

Source:http://linkedlifedata.com/resource/pubmed/id/20213078

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0030705, umls-concept:C0123931, umls-concept:C0278701, umls-concept:C0442034, umls-concept:C0442120, umls-concept:C0920321, umls-concept:C1705192
pubmed:issue	1
pubmed:dateCreated	2011-1-3
pubmed:abstractText	The objectives of this phase I study were to determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLTs), and preliminary efficacy of intraperitoneally administered irinotecan (CPT-11) in gastric cancer patients with peritoneal seeding.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7806519
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Phytogenic, http://linkedlifedata.com/resource/pubmed/chemical/Camptothecin, http://linkedlifedata.com/resource/pubmed/chemical/irinotecan
pubmed:status	MEDLINE
pubmed:month	Jan
pubmed:issn	1432-0843
pubmed:author	pubmed-author:AhnByung-JinBJ, pubmed-author:ChoiMoon KiMK, pubmed-author:HeoJin SeokJS, pubmed-author:KangWon KiWK, pubmed-author:KimSungS, pubmed-author:LeeJeeyunJ, pubmed-author:LimHo YeongHY, pubmed-author:NohJae HyungJH, pubmed-author:ParkJoon OhJO, pubmed-author:ParkSe HoonSH, pubmed-author:ParkYoung SukYS, pubmed-author:SohnTae SungTS, pubmed-author:YimDong-SeokDS
pubmed:issnType	Electronic
pubmed:volume	67
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	5-11
pubmed:meshHeading	pubmed-meshheading:20213078-Adenocarcinoma, pubmed-meshheading:20213078-Adult, pubmed-meshheading:20213078-Antineoplastic Agents, Phytogenic, pubmed-meshheading:20213078-Camptothecin, pubmed-meshheading:20213078-Diarrhea, pubmed-meshheading:20213078-Disease-Free Survival, pubmed-meshheading:20213078-Dose-Response Relationship, Drug, pubmed-meshheading:20213078-Female, pubmed-meshheading:20213078-Fever, pubmed-meshheading:20213078-Follow-Up Studies, pubmed-meshheading:20213078-Gastrectomy, pubmed-meshheading:20213078-Humans, pubmed-meshheading:20213078-Infusions, Parenteral, pubmed-meshheading:20213078-Male, pubmed-meshheading:20213078-Maximum Tolerated Dose, pubmed-meshheading:20213078-Middle Aged, pubmed-meshheading:20213078-Neutropenia, pubmed-meshheading:20213078-Peritoneal Dialysis, Continuous Ambulatory, pubmed-meshheading:20213078-Peritoneal Neoplasms, pubmed-meshheading:20213078-Stomach Neoplasms
pubmed:year	2011
pubmed:articleTitle	Phase I study of intraperitoneal irinotecan in patients with gastric adenocarcinoma with peritoneal seeding.
pubmed:affiliation	Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul 135-710, Korea.
pubmed:publicationType	Journal Article, Clinical Trial, Phase I